UruguayTuberculosis profile
Population  2014 3.4 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.057 (0.054–0.06) 1.7 (1.6–1.7)
Mortality (HIV+TB only) 0.024 (0.017–0.032) 0.7 (0.51–0.92)
Prevalence  (includes HIV+TB) 1.2 (0.53–2.1) 35 (16–62)
Incidence  (includes HIV+TB) 1 (0.91–1.2) 30 (27–34)
Incidence (HIV+TB only) 0.16 (0.14–0.18) 4.7 (4–5.3)
         
Case detection, all forms (%) 83 (73–95)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0 (0–0.79) 2.4 (0.06–13)
MDR-TB cases among notified pulmonary
TB cases
0 (0–6) 2 (0–11)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 536   50
Pulmonary, clinically diagnosed 180   12
Extrapulmonary 83   1
       
Total new and relapse 862    
Previously treated, excluding relapses 26    
Total cases notified 888    
Among 862 new and relapse cases:
57 (7%) cases aged under 15 years; male:female ratio: 2.1
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 370 (69%) 35 (39%) 405
Laboratory-confirmed RR-/MDR-TB cases     2
Patients started on MDR-TB treatment ***     2
TB/HIV 2014 Number (%)
TB patients with known HIV status 809 (91)
HIV-positive TB patients 132 (16)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 73 (55)
HIV-positive TB patients on antiretroviral therapy (ART) 68 (52)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (79) 878
Previously treated cases, excluding relapse, registered in 2013 (67) 18
HIV-positive TB cases, all types, registered in 2013 (61) 119
RR-/MDR-TB cases started on second-line treatment in 2012 (100) 1
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) <0.1
Culture (per 5 million population) 1.5
Drug susceptibility testing (per 5 million population) 1.5
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 4.2
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-24 Data: www.who.int/tb/data